Ani Pharmaceuticals Inc (ANIP)
Sector: Healthcare
Industry: Pharmaceutical Preparations
Country: United States
Exchange: NASDAQ
Market cap: $1.75B
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
Latest financial period: June 30, 2026
Filed with the SEC: August 7, 2026
Estimated earnings date: November 6, 2026
Profit #456 of 1484 companies
| | Jun 26 | Mar 26 | Dec 25 | Sep 25 |
|---|
| ROIC | 15.0% | 11.8% | 10.6% | 7.3% |
Growth #162 of 1484 companies
Payout #689 of 1484 companies
Safety #870 of 1484 companies
Price #200 of 1484 companies
